What this is
- How it works
- How it works isn't classified yet
- Tested for
- Asthma (2 trials)
- Main trialPhase 3
- “The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.”In the company’s words, NCT06323213 on ClinicalTrials.gov
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- DepemokimabGSK · Phase 3
Coming up2
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2027 | Efficacy and Safety Study of 610 in Patients With Severe Asthma | |
| Phase 2Active, not recruiting | Feb 2027 | A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026